Structural and molecular bases to IRE1 activity modulation. Issue 15 (13th August 2021)

• Record Type: Journal Article
• Authors: Langlais, Timothy; Pelizzari-Raymundo, Diana; Mahdizadeh, Sayyed Jalil; Gouault, Nicolas; Carreaux, Francois; Chevet, Eric; Eriksson, Leif A.; Guillory, Xavier
• Is Part Of: Biochemical journal. Volume 478:Issue 15(2021)
• Page Start: 2953
• Page End: 2975
• Publication Date: 2021-08-13
• Subjects: ER stress -- IRE1 -- structure activity relationship (SAR) -- structure-based drug design (SBDD) -- unfolded protein response; Biochemistry -- Periodicals; 572
• DOI: 10.1042/BCJ20200919
• Languages: English
• ISSNs: 0264-6021

Abstract

Abstract : The Unfolded Protein response is an adaptive pathway triggered upon alteration of endoplasmic reticulum (ER) homeostasis. It is transduced by three major ER stress sensors, among which the Inositol Requiring Enzyme 1 (IRE1) is the most evolutionarily conserved. IRE1 is an ER-resident type I transmembrane protein exhibiting an ER luminal domain that senses the protein folding status and a catalytic kinase and RNase cytosolic domain. In recent years, IRE1 has emerged as a relevant therapeutic target in various diseases including degenerative, inflammatory and metabolic pathologies and cancer. As such several drugs altering IRE1 activity were developed that target either catalytic activity and showed some efficacy in preclinical pathological mouse models. In this review, we describe the different drugs identified to target IRE1 activity as well as their mode of action from a structural perspective, thereby identifying common and different modes of action. Based on this information we discuss on how new IRE1-targeting drugs could be developed that outperform the currently available molecules.